PIPE (Private Investment in Public Equity)
Also known as PIPE Deal, PIPE Offering, Private Investment in Public Equity
A PIPE is a private placement of equity or convertible securities into a company that is already publicly traded. The issuer sells restricted shares (or convertible notes, preferred, or warrants) to accredited investors at a negotiated price, then files a resale registration statement so investors can later sell into the public market.
In depth
A PIPE solves a specific public-company problem: raise material capital fast, without the time and execution risk of a traditional follow-on. The issuer negotiates with a small group of institutional buyers, agrees on price and structure in private, signs purchase agreements, closes the placement under Regulation D, and then files a resale registration statement so the buyers can eventually sell the restricted shares into the public market.
Structure varies more than founders realize. The simplest version is common stock at a discount to the volume-weighted average price over the prior trading window. Growth-stage and biotech deals often layer in warrants alongside the common, sometimes pre-funded warrants that function as common-equivalent shares with a near-zero strike. Convertible preferred and convertible debt PIPEs appear when the issuer wants to defer dilution at the cost of higher coupons.
The NVCA publishes Model PIPE Financing Documents (US Issuer and Foreign Private Issuer versions, with Pre-Funded and Common Warrant forms) that have become the closest thing to a market standard. Before 2022 most PIPE paper was bespoke. The model documents have shortened negotiation cycles, particularly in biotech where PIPEs anchor a large share of funding events.
Why it matters
PIPEs are how public growth companies raise capital outside the standard follow-on path. For biotech, where clinical trial readouts create discrete capital needs, PIPEs let the company size a raise to a specific data event rather than waiting for an open market window. For SPAC sponsors, PIPEs are the institutional anchor that validates the de-SPAC valuation. For distressed public companies, PIPEs are the only realistic path to recapitalization when a follow-on would price at unacceptable discount.
The structure carries reputational risk. PIPEs that include variable conversion or aggressive reset features have historically destroyed shareholder value in distressed situations. Investors read the PIPE structure as a signal about how confident the company is in its near-term stock price.
Worked example
A public biotech with a $400M market cap needs $80M to fund a Phase 3 trial. The board approves a PIPE rather than a marketed follow-on.
| Component | Amount | Terms |
|---|---|---|
| Common stock | $50M | $10.00/share (15% discount to 5-day VWAP of $11.75) |
| Pre-funded warrants | $30M | $9.9999/share strike, no expiration |
| Common warrants | issued alongside | 50% coverage, $13.00/share strike, 5-year |
PIPE shares issued (common) = $50M / $10.00 = 5.0M shares
Pre-funded warrant shares = $30M / $10.00 = 3.0M shares (effectively common)
Common warrants on 50% coverage = 4.0M shares at $13 (upside for investors)
Total post-PIPE shares outstanding = previous 40M + 8M = 48M (20% dilution)
Investors deploy $80M today, receive 8M common-equivalent shares at $10.00, plus warrants for another 4M at $13.00. If the Phase 3 reads out positive and the stock trades to $25, the warrants are worth roughly $48M of intrinsic value, on top of the $200M mark on the underlying shares. The structure prices clinical risk explicitly.
Frequently asked
Why does a public company raise via a PIPE instead of a follow-on offering?
Speed and certainty. A registered follow-on takes weeks and exposes pricing to the market. A PIPE closes in days, the buyer pool is pre-committed, and the issuer can price the deal privately. The trade-off is a discount to the public market price and resale registration obligations.
What securities can be sold in a PIPE?
Common stock is most common, but PIPEs can also be convertible preferred stock, convertible debentures, warrants, or a structured combination. The NVCA Model PIPE Documents include both Pre-Funded Warrants and Common Warrant forms, which appear in many growth-stage and biotech PIPE deals.
Who can buy a PIPE?
Accredited investors, almost always institutional. The SEC notes PIPEs are typically sold to selected institutional accredited investors, which keeps the placement under Regulation D and avoids the registration burden of a public offering. Retail investors buy the resold shares later once the registration statement is effective.
What is a structured PIPE?
A structured PIPE includes reset features, variable conversion ratios, or other terms that shift dilution to existing shareholders if the stock price declines. Death-spiral PIPEs are an extreme version, where conversion floats inversely to stock price, creating a feedback loop that can wipe out common holders. Most modern PIPEs are simpler fixed-price deals.